Opposite to the above results, Takeda et al.27 reported that SLC31A1 was predominantly expressed in triple-negative breast cancer resistant to TA-based neoadjuvant chemotherapy. The gene discussed is SLC31A1; the disease is triple-negative breast carcinoma.